TG Therapeutics Inc Forecasted to Earn FY2022 Earnings of $1.12 Per Share (TGTX)

TG Therapeutics Inc (NASDAQ:TGTX) – Equities researchers at Jefferies Group issued their FY2022 EPS estimates for TG Therapeutics in a report issued on Tuesday. Jefferies Group analyst M. Andrews expects that the biopharmaceutical company will post earnings of $1.12 per share for the year.

Several other equities research analysts also recently issued reports on TGTX. HC Wainwright reissued a “buy” rating and issued a $33.00 price objective (up from $18.00) on shares of TG Therapeutics in a research note on Tuesday, November 14th. B. Riley began coverage on TG Therapeutics in a report on Friday, December 1st. They set a “buy” rating and a $21.50 price target for the company. Raymond James Financial reissued a “buy” rating on shares of TG Therapeutics in a research note on Tuesday, December 12th. BidaskClub raised TG Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, January 11th. Finally, Zacks Investment Research lowered TG Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, January 13th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and nine have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $25.50.

Shares of TG Therapeutics (NASDAQ:TGTX) traded down $0.25 during midday trading on Wednesday, hitting $11.60. The stock had a trading volume of 777,800 shares, compared to its average volume of 1,748,506. TG Therapeutics has a twelve month low of $4.50 and a twelve month high of $15.35. The stock has a market capitalization of $844.29, a P/E ratio of -6.55 and a beta of 1.67.

Hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Inc. increased its position in shares of TG Therapeutics by 3.5% during the fourth quarter. BlackRock Inc. now owns 3,414,999 shares of the biopharmaceutical company’s stock valued at $28,003,000 after buying an additional 115,252 shares during the period. State Street Corp lifted its position in TG Therapeutics by 274.4% during the second quarter. State Street Corp now owns 2,638,683 shares of the biopharmaceutical company’s stock valued at $26,515,000 after purchasing an additional 1,933,896 shares during the period. Franklin Resources Inc. lifted its position in TG Therapeutics by 3.7% during the fourth quarter. Franklin Resources Inc. now owns 2,457,415 shares of the biopharmaceutical company’s stock valued at $20,151,000 after purchasing an additional 87,398 shares during the period. Vanguard Group Inc. lifted its position in TG Therapeutics by 14.3% during the second quarter. Vanguard Group Inc. now owns 2,046,427 shares of the biopharmaceutical company’s stock valued at $20,566,000 after purchasing an additional 255,844 shares during the period. Finally, Columbus Circle Investors lifted its position in TG Therapeutics by 9.8% during the third quarter. Columbus Circle Investors now owns 1,532,911 shares of the biopharmaceutical company’s stock valued at $18,165,000 after purchasing an additional 136,515 shares during the period. 47.44% of the stock is owned by institutional investors.

In related news, CFO Sean A. Power sold 32,006 shares of TG Therapeutics stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $8.50, for a total value of $272,051.00. Following the completion of the transaction, the chief financial officer now directly owns 517,464 shares in the company, valued at approximately $4,398,444. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 16.70% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “TG Therapeutics Inc Forecasted to Earn FY2022 Earnings of $1.12 Per Share (TGTX)” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of U.S. and international copyright & trademark legislation. The correct version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/02/14/tg-therapeutics-inc-forecasted-to-earn-fy2022-earnings-of-1-12-per-share-tgtx.html.

About TG Therapeutics

TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.

Earnings History and Estimates for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply